#1 Clinical Trials Search in Europe

Palonosetron Hydrochloride

Palonosetron Hydrochloride is a medication being studied in clinical trials for its effectiveness in preventing nausea and vomiting, particularly in cancer patients undergoing chemotherapy or radiation therapy. These trials aim to evaluate different formulations, dosages, and combinations with other drugs to optimize its antiemetic effects and improve patient quality of life during cancer treatment.

Table of Contents

What is Palonosetron Hydrochloride?

Palonosetron Hydrochloride is a medication primarily used to prevent nausea and vomiting. It belongs to a class of drugs called 5-HT3 receptor antagonists, which work by blocking certain chemical signals in the body that can trigger nausea and vomiting[1]. This drug is also known by its brand name Aloxi[2].

Uses of Palonosetron Hydrochloride

Palonosetron Hydrochloride is primarily used in the following situations:

  • Chemotherapy-Induced Nausea and Vomiting (CINV): It helps prevent nausea and vomiting caused by cancer chemotherapy, especially moderately and highly emetogenic (likely to cause vomiting) chemotherapy[1].
  • Radiation Therapy-Induced Nausea and Vomiting: It may be used to prevent nausea and vomiting in patients undergoing radiation therapy for abdominal cancers[3].
  • Opioid-Induced Nausea and Vomiting (OINV): Research is being conducted to evaluate its effectiveness in preventing nausea and vomiting caused by opioid pain medications in palliative care patients[4].

How Palonosetron Hydrochloride Works

Palonosetron Hydrochloride works by blocking the action of serotonin, a natural substance in the body that can cause nausea and vomiting. Specifically, it blocks serotonin at the 5-HT3 receptors in the small intestine. By doing this, it helps prevent the nausea and vomiting reflex[1].

Administration and Dosage

Palonosetron Hydrochloride can be administered in several ways:

  • Intravenous (IV) Injection: Often given as a 0.25 mg dose about 30 minutes before chemotherapy[5].
  • Oral Capsules: Available as 0.5 mg capsules, typically taken about 1 hour before chemotherapy[6].
  • Buccal Film: A new form being researched where the medication is delivered through a film placed in the cheek[7].

The exact dosage and schedule can vary depending on the specific treatment and the patient’s needs. Always follow your healthcare provider’s instructions.

Effectiveness

Palonosetron Hydrochloride has shown effectiveness in preventing nausea and vomiting in various clinical trials. Its effectiveness is often measured by the “complete response” rate, which means no vomiting and no need for rescue medication[2]. Studies have shown it to be effective in both the acute phase (first 24 hours after chemotherapy) and the delayed phase (24-120 hours after chemotherapy)[8].

Potential Side Effects

While Palonosetron Hydrochloride is generally well-tolerated, like all medications, it can have side effects. Common side effects may include:

  • Headache
  • Constipation
  • Fatigue

Serious side effects are rare but can occur. It’s important to report any unusual symptoms to your healthcare provider[4].

Ongoing Research

Researchers are continually studying Palonosetron Hydrochloride to improve its effectiveness and explore new uses. Some areas of ongoing research include:

  • Combination Therapy: Studying the effectiveness of combining Palonosetron with other anti-nausea medications like Netupitant[9].
  • New Delivery Methods: Investigating the use of buccal films for easier administration[7].
  • Extended Use: Evaluating its effectiveness in preventing chronic nausea and vomiting in cancer patients[9].
  • Use in Radiation Therapy: Studying its effectiveness in preventing nausea and vomiting caused by radiation therapy[3].

These ongoing studies aim to improve the quality of life for patients undergoing cancer treatments or dealing with chronic nausea and vomiting.

Aspect Details
Primary Use Prevention of chemotherapy-induced nausea and vomiting (CINV)
Other Applications Radiation therapy-induced nausea and vomiting, opioid-induced nausea and vomiting in palliative care
Formulations Studied Intravenous (IV) injection, oral capsules, buccal films
Key Outcome Measures Complete response rate, time to first emetic episode, use of rescue medication, patient-reported nausea severity
Combination Therapies Often studied in combination with other antiemetics like Netupitant or dexamethasone
Patient Populations Cancer patients undergoing chemotherapy or radiation therapy, palliative care patients on opioids
Safety Monitoring Adverse events, tolerability of different dosages and formulations

FAQ

  • What is Palonosetron Hydrochloride used for in clinical trials? Palonosetron Hydrochloride is primarily being studied for its ability to prevent chemotherapy-induced nausea and vomiting (CINV) in cancer patients. It's also being tested for preventing nausea and vomiting caused by radiation therapy and opioid use in palliative care.
  • How is Palonosetron Hydrochloride administered in these trials? The medication is being tested in various forms, including intravenous (IV) injections, oral capsules, and buccal films (which dissolve in the mouth). The dosage and frequency of administration vary depending on the specific trial and treatment regimen.
  • What are some of the potential benefits of Palonosetron Hydrochloride? Clinical trials are investigating whether Palonosetron Hydrochloride can provide longer-lasting relief from nausea and vomiting compared to other antiemetics. Some studies are also looking at its effectiveness when combined with other medications to enhance its antiemetic effects.
  • Are there any side effects being monitored in these trials? While specific side effects vary between trials, researchers are generally monitoring for any adverse events related to the medication. This includes evaluating the tolerability of different dosages and formulations of Palonosetron Hydrochloride.
  • How do researchers measure the effectiveness of Palonosetron Hydrochloride in these trials? Effectiveness is often measured by the 'complete response' rate, which typically means no vomiting and no use of rescue medication. Researchers also assess factors like the severity of nausea, time to first vomiting episode, and overall patient satisfaction with the treatment.

Ongoing Clinical Trials on Palonosetron Hydrochloride

  • Study on IV NEPA (Fosnetupitant/Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Poland Romania

  • Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Norway Sweden

Glossary

  • Antiemetic: A medication used to prevent or reduce nausea and vomiting.
  • CINV: Chemotherapy-Induced Nausea and Vomiting, a common side effect experienced by cancer patients undergoing chemotherapy treatment.
  • Buccal film: A thin, flexible strip of medication that dissolves when placed between the cheek and gum or under the tongue.
  • Emetogenic: Capable of causing nausea or vomiting. In cancer treatment, chemotherapy drugs are often classified as highly, moderately, or low emetogenic.
  • Complete response: In antiemetic trials, this typically means the patient experiences no vomiting and does not require any additional (rescue) medication for nausea or vomiting.
  • Rescue medication: Additional medication given to treat breakthrough symptoms, in this case, nausea or vomiting that occurs despite preventive treatment.
  • Acute phase: In CINV, this refers to the first 24 hours after chemotherapy administration.
  • Delayed phase: In CINV, this refers to the period from 24 to 120 hours after chemotherapy administration.
  • 5-HT3 receptor antagonist: A class of drugs, including Palonosetron, that work by blocking a specific type of serotonin receptor involved in triggering nausea and vomiting.
  • Quality of life: A measure of an individual's overall well-being and ability to function in daily life, often assessed in clinical trials to determine the impact of a treatment on patients.

References

  1. https://clinicaltrials.gov/study/NCT01481831
  2. https://clinicaltrials.gov/study/NCT03097588
  3. https://clinicaltrials.gov/study/NCT00903396
  4. https://clinicaltrials.gov/study/NCT05315999
  5. https://clinicaltrials.gov/study/NCT06427681
  6. https://clinicaltrials.gov/study/NCT05690802
  7. https://clinicaltrials.gov/study/NCT05199818
  8. https://clinicaltrials.gov/study/NCT04592198
  9. https://clinicaltrials.gov/study/NCT03040726